Comparative Pharmacology
Head-to-head clinical analysis: LONOX versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONOX versus LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE.
LONOX vs LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is an opioid receptor agonist that acts on mu-opioid receptors in the myenteric plexus of the large intestine, inhibiting peristalsis and prolonging transit time. It also reduces colonic water and electrolyte secretion, enhancing fluid and electrolyte absorption. Loperamide has low systemic bioavailability due to extensive first-pass metabolism and is not significantly absorbed into the central nervous system due to P-glycoprotein efflux transport.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
1-2 mg orally every 6 hours as needed for diarrhea; maximum 8 mg per day.
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged (up to 30 h) in elderly and renal impairment.
Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment.
Primarily renal (60-70% as unchanged drug and active metabolite); biliary/fecal ~20%.
Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces.
Category C
Category A/B
Antidiarrheal
Antidiarrheal